Early phase 1Active, not recruiting
TAME: A Pilot Study of Weekly Paclitaxel, Bevacizumab, and Tumor Associated Macrophage Targeted Therapy (Zoledronic Acid) in Women With Recurrent, Platinum-resistant, Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- Sponsor
- M.D. Anderson Cancer Center (Academic or other)
- Enrolment
- 14 enrolled
- Conditions
- Epithelial Ovarian; Fallopian Tube; Primary Peritoneal Cancer
- Interventions
- Paclitaxel/Bev (control); Paclitaxel/Bev + ZA (experimental)
- Ages
- adults, older adults
- Registry
- NCT05053750
Full record on ClinicalTrials.gov
From the registry
This is a randomized pilot trial of weekly paclitaxel and bevacizumab with or without zoledronic acid in women with platinum-resistant epithelial ovarian cancer with 1-2 prior regimens for recurrence.
Primary outcomes
- To assess macrophage counts by image cytometry in women with platinum resistant ovarian cancer treated with weekly paclitaxel/bevacizumab and ZA relative to weekly paclitaxel/bevacizumab
History
Primary completion expected
Last registry update
Started
Registered